U.S. Markets open in 1 hr 13 mins

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
315.03-3.97 (-1.24%)
At close: 4:00PM EDT

314.03 -1.00 (-0.32%)
Pre-Market: 7:17AM EDT

People also watch
CELGREGNGILDAMGNALXN
Full screen
Previous Close319.00
Open316.39
Bid311.10 x 100
Ask319.90 x 100
Day's Range314.44 - 317.96
52 Week Range244.28 - 330.00
Volume934,729
Avg. Volume1,305,178
Market Cap66.61B
Beta0.50
PE Ratio (TTM)20.67
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Editor's Pick
    Yahoo Finance21 hours ago

    Today's charts: Tesla, AMD developing new AI chip; Blue Apron shares gain; Biogen downgrade; Amazon expands in New York

    Tesla (TSLA) is teaming up with AMD (AMD) to develop its own AI chip for self-driving cars, according to a report by CNBC. Jefferies analyst Mark Lipacis wrote it’s a “critical win” for AMD. On the other hand, Nvidia (NVDA) shares are falling on the news, since a partnership with AMD would make Tesla less reliant on the company.

  • Investopedia2 hours ago

    Gilead, Amgen, and Biogen May Lift Biotech Higher

    These drug juggernauts could bolster the entire biotechnology sector as we head toward year-end.

  • Barrons.com21 hours ago

    Biogen: Buy or Hold?

    Just as one analyst goes bullish on Biogen (BIIB), another has moved to the sidelines. Earlier today, Raymond James analyst Laura Chico cut her rating on the stock by two notches, from a Strong Buy to a Market Perform (skipping over Outperform entirely) and lowered her price target from $329 a share to $319 a share. Chico sees continued headwinds for Biogen’s all-important multiple sclerosis drug franchise as a rival drug from Roche (RHHBY) gains market share.